skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 40  for All Library Resources

Results 1 2 next page
Refined by: New Records: New From Last Month remove subject: Cholesterol remove subject: Coronary Vessels remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Recurrent Acute Coronary Syndrome in Young Man with Familial Hypercholesterolemia: Efficacy of Evolocumab Add-On Treatment Demonstrated via Serial Coronary Angiography
Material Type:
Article
Add to My Research

Recurrent Acute Coronary Syndrome in Young Man with Familial Hypercholesterolemia: Efficacy of Evolocumab Add-On Treatment Demonstrated via Serial Coronary Angiography

Biomedicines, 2024-05, Vol.12 (5), p.1113 [Peer Reviewed Journal]

COPYRIGHT 2024 MDPI AG ;2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2227-9059 ;EISSN: 2227-9059 ;DOI: 10.3390/biomedicines12051113 ;PMID: 38791076

Full text available

2
Role of miR-128-3p and miR-195-5p as biomarkers of coronary artery disease in Indians: a pilot study
Material Type:
Article
Add to My Research

Role of miR-128-3p and miR-195-5p as biomarkers of coronary artery disease in Indians: a pilot study

Scientific reports, 2024-05, Vol.14 (1), p.11881-11881 [Peer Reviewed Journal]

2024. The Author(s). ;The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;EISSN: 2045-2322 ;DOI: 10.1038/s41598-024-61077-4 ;PMID: 38789551

Full text available

3
The ABCs of the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease
Material Type:
Article
Add to My Research

The ABCs of the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease

Clinical cardiology (Mahwah, N.J.), 2024-05, Vol.47 (5), p.e24284-n/a [Peer Reviewed Journal]

2024 The Author(s). published by Wiley Periodicals LLC. ;2024 The Author(s). Clinical Cardiology published by Wiley Periodicals LLC. ;2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 0160-9289 ;EISSN: 1932-8737 ;DOI: 10.1002/clc.24284 ;PMID: 38766996

Full text available

4
The causal relationship between sarcopenia‐related traits and ischemic stroke: Insights from univariable and multivariable Mendelian randomization analyses
Material Type:
Article
Add to My Research

The causal relationship between sarcopenia‐related traits and ischemic stroke: Insights from univariable and multivariable Mendelian randomization analyses

CNS neuroscience & therapeutics, 2024-05, Vol.30 (5), p.e14759-n/a [Peer Reviewed Journal]

2024 The Authors. published by John Wiley & Sons Ltd. ;2024 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd. ;2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1755-5930 ;EISSN: 1755-5949 ;DOI: 10.1111/cns.14759 ;PMID: 38757378

Full text available

5
Identifying risk factors and mortality rate of premature coronary artery disease in young Saudi population
Material Type:
Article
Add to My Research

Identifying risk factors and mortality rate of premature coronary artery disease in young Saudi population

Scientific reports, 2024-06, Vol.14 (1), p.12727-12727 [Peer Reviewed Journal]

The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2024 ;EISSN: 2045-2322 ;DOI: 10.1038/s41598-024-62970-8 ;PMID: 38830947

Full text available

6
Osteocalcin: A Potential Marker of Peripheral Arterial Stiffness in Hypertensive Patients
Material Type:
Article
Add to My Research

Osteocalcin: A Potential Marker of Peripheral Arterial Stiffness in Hypertensive Patients

Medicina (Kaunas, Lithuania), 2024-05, Vol.60 (5), p.835 [Peer Reviewed Journal]

COPYRIGHT 2024 MDPI AG ;2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1648-9144 ;ISSN: 1010-660X ;EISSN: 1648-9144 ;DOI: 10.3390/medicina60050835 ;PMID: 38793018

Full text available

7
Atherogenic index of plasma as a predictor of coronary artery disease: a cohort study in south of Iran
Material Type:
Article
Add to My Research

Atherogenic index of plasma as a predictor of coronary artery disease: a cohort study in south of Iran

The Egyptian heart journal, 2024-05, Vol.76 (1), p.65-65 [Peer Reviewed Journal]

The Author(s) 2024 ;2024. The Author(s). ;COPYRIGHT 2024 Springer ;The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1110-2608 ;EISSN: 2090-911X ;DOI: 10.1186/s43044-024-00497-z ;PMID: 38806969

Full text available

8
Evolocumab Treatment in Dyslipidemic Patients Undergoing Coronary Artery Bypass Grafting: One-Year Safety and Efficacy Results
Material Type:
Article
Add to My Research

Evolocumab Treatment in Dyslipidemic Patients Undergoing Coronary Artery Bypass Grafting: One-Year Safety and Efficacy Results

Journal of clinical medicine, 2024-05, Vol.13 (10), p.2987 [Peer Reviewed Journal]

COPYRIGHT 2024 MDPI AG ;2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2077-0383 ;EISSN: 2077-0383 ;DOI: 10.3390/jcm13102987 ;PMID: 38792527

Full text available

9
A Retrospective Analysis of the Effects of Cardiac Rehabilitation on Health Markers and Performance Outcomes among Diabetic and Non-Diabetic Patients with Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention
Material Type:
Article
Add to My Research

A Retrospective Analysis of the Effects of Cardiac Rehabilitation on Health Markers and Performance Outcomes among Diabetic and Non-Diabetic Patients with Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention

Sports (Basel), 2024-05, Vol.12 (5), p.122 [Peer Reviewed Journal]

COPYRIGHT 2024 MDPI AG ;2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2075-4663 ;EISSN: 2075-4663 ;DOI: 10.3390/sports12050122 ;PMID: 38786991

Full text available

10
Cholesterol test
Material Type:
Reports
Add to My Research

Cholesterol test

Mayo Clinic Health Information Library : Tests & Procedures, 2024

2024 Mayo Foundation for Medical Education and Research (MRMER). All rights reserved.

Digital Resources/Online E-Resources

11
Cholesterol test
Material Type:
Reports
Add to My Research

Cholesterol test

Mayo Clinic Health Information Library : Tests & Procedures, 2024

2024 Mayo Foundation for Medical Education and Research (MRMER). All rights reserved.

Digital Resources/Online E-Resources

12
Cholesterol test
Material Type:
Reports
Add to My Research

Cholesterol test

Mayo Clinic Health Information Library : Tests & Procedures, 2024

2024 Mayo Foundation for Medical Education and Research (MRMER). All rights reserved.

Digital Resources/Online E-Resources

13
Verve Therapeutics (VERV: $5.14) rises 4.9% from 14-day low; +6c [1.2%] Vol Index 1.3 [1 is avg]
Material Type:
Newsletter Article
Add to My Research

Verve Therapeutics (VERV: $5.14) rises 4.9% from 14-day low; +6c [1.2%] Vol Index 1.3 [1 is avg]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 31, 2024

Digital Resources/Online E-Resources

14
Cholesterol test
Material Type:
Reports
Add to My Research

Cholesterol test

Mayo Clinic Health Information Library : Tests & Procedures, 2024

2024 Mayo Foundation for Medical Education and Research (MRMER). All rights reserved.

Digital Resources/Online E-Resources

15
Verve Therapeutics (VERV: $5.24) hits year-low 16th time in three months; -4c [0.8%]
Material Type:
Newsletter Article
Add to My Research

Verve Therapeutics (VERV: $5.24) hits year-low 16th time in three months; -4c [0.8%]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 29, 2024

Digital Resources/Online E-Resources

16
Verve Therapeutics (VERV: $5.58) increases on firm volume; +4c [0.7%] Vol Index 1.3 [1 is avg]
Material Type:
Newsletter Article
Add to My Research

Verve Therapeutics (VERV: $5.58) increases on firm volume; +4c [0.7%] Vol Index 1.3 [1 is avg]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 23, 2024

Digital Resources/Online E-Resources

17
Verve Therapeutics (VERV: $5.54) hits year-low 12th time in three months; -41c [6.9%] Vol Index 1.2 [1 is avg]
Material Type:
Newsletter Article
Add to My Research

Verve Therapeutics (VERV: $5.54) hits year-low 12th time in three months; -41c [6.9%] Vol Index 1.2 [1 is avg]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 22, 2024

Digital Resources/Online E-Resources

18
Verve Therapeutics (VERV: $5.95) hits year-low 11th time in three months; -3c [0.5%] Vol Index 1.3 [1 is avg]
Material Type:
Newsletter Article
Add to My Research

Verve Therapeutics (VERV: $5.95) hits year-low 11th time in three months; -3c [0.5%] Vol Index 1.3 [1 is avg]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 21, 2024

Digital Resources/Online E-Resources

19
Weekly: Verve Therapeutics (VERV: $5.98) decreases 0.5% on robust volume; -3c [0.5%] Vol Index 1.5 [1 is avg]
Material Type:
Newsletter Article
Add to My Research

Weekly: Verve Therapeutics (VERV: $5.98) decreases 0.5% on robust volume; -3c [0.5%] Vol Index 1.5 [1 is avg]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 20, 2024

Digital Resources/Online E-Resources

20
Verve Therapeutics (VERV: $5.98) tumbles 6.3% weakening below moving average price; -40c [6.3%] Vol Index 1.8 [1 is avg]
Material Type:
Newsletter Article
Add to My Research

Verve Therapeutics (VERV: $5.98) tumbles 6.3% weakening below moving average price; -40c [6.3%] Vol Index 1.8 [1 is avg]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 18, 2024

Digital Resources/Online E-Resources

Results 1 - 20 of 40  for All Library Resources

Results 1 2 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Searching Remote Databases, Please Wait